KZR vs. NXTC, HOOK, RENB, ZVRA, GLSI, TRVI, IVA, ABEO, CAPR, and ANL
Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include NextCure (NXTC), Hookipa Pharma (HOOK), Renovaro (RENB), Zevra Therapeutics (ZVRA), Greenwich LifeSciences (GLSI), Trevi Therapeutics (TRVI), Inventiva (IVA), Abeona Therapeutics (ABEO), Capricor Therapeutics (CAPR), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical preparations" industry.
NextCure (NASDAQ:NXTC) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.
NextCure's return on equity of -47.28% beat Kezar Life Sciences' return on equity.
NextCure has higher earnings, but lower revenue than Kezar Life Sciences. NextCure is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
Kezar Life Sciences received 56 more outperform votes than NextCure when rated by MarketBeat users. However, 63.93% of users gave NextCure an outperform vote while only 58.01% of users gave Kezar Life Sciences an outperform vote.
NextCure has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.
In the previous week, Kezar Life Sciences had 1 more articles in the media than NextCure. MarketBeat recorded 1 mentions for Kezar Life Sciences and 0 mentions for NextCure. Kezar Life Sciences' average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.
42.7% of NextCure shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 13.3% of NextCure shares are owned by insiders. Comparatively, 9.3% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
NextCure presently has a consensus price target of $6.00, indicating a potential upside of 331.65%. Kezar Life Sciences has a consensus price target of $11.00, indicating a potential upside of 1,506.54%. Given NextCure's higher possible upside, analysts plainly believe Kezar Life Sciences is more favorable than NextCure.
Summary
Kezar Life Sciences beats NextCure on 9 of the 15 factors compared between the two stocks.
Get Kezar Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kezar Life Sciences Competitors List
Related Companies and Tools
